Caribou Biosciences

Valuation Analysis

About the Company

Caribou Biosciences en bref

Caribou Biosciences (CRBU) is currently trading at 1,43 € with a market capitalization of 142 M €. The 52-week range spans from 1,05 € to 3,09 €; the current price is 53.7% below the yearly high. Year-over-year revenue growth stands at +1.9%.

💰 Dividende

Caribou Biosciences currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent Caribou Biosciences (CRBU) au consensus : Achat Fort. L'objectif de cours moyen est de 10,46 €, soit un potentiel de +631.71% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 3,49 € à 27,90 €.

Caribou Biosciences : la thèse d'investissement en détail

Caribou Biosciences (CRBU) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 631.71% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 1.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a beta near 2.33, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 631.71% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (7.82%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Caribou Biosciences?

Compare top-rated brokers — low fees, trusted providers, fully regulated.